Exceptional Responders With Pancreatic Cancer to Chemotherapy
Status:
Enrolling by invitation
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is an observational study enrolling patients with pancreatic cancer to identify genomic
expression differences between exceptional responders and non-responders to standard of care
chemotherapy. Data analysis of the gene expression profile of the exceptional responders
compared to non-responders will define genomic patterns that may help understand their
response to chemotherapy.
Details
Lead Sponsor:
Adera Labs, LLC
Collaborators:
Hematology and Oncology Specialists Maastricht University Medical Center Memorial Sloan Kettering Cancer Center The Pancreatic Cancer Treatment Center of Los Angeles University of Nebraska Weill Medical College of Cornell University